Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
May 31st 2020Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.
Watch
Evaluating Future Steps for Investigating Seleno-L-Methionine in RCC
May 28th 2020Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.
Watch